Details of the Drug

General Information of Drug (ID: DMI6HUW)

Drug Name
Terbinafine
Synonyms
Bramazil; Lamasil; TerbiFoam; Terbina; Lamisil AT; Lamisil Tablet; Ternbinafine HCl; Lamasil (TN); Lamisil (TN); SF 86-327; Terbisil (TN); Zabel (TN); SF-86-327; Terbinafine (USAN/INN); Terbinafine [USAN:BAN:INN]; Lamisil, Terbinex, Corbinal, Zabel, Terbinafine; Terbinafine, SF-86-327, Lamisil, TBNF; (2E)-N,6,6-trimethyl-N-(1-naphthylmethyl)-2-hepten-4-yn-1-amine; (2E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine; (E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine; (E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalene methanamine; (E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethylamine; (E)-N-(6,6-dimethyl-2-heptenynyl)-N-methyl-1-naphthalenementhamin hydrochloride
Indication
Disease Entry ICD 11 Status REF
Fungal infection 1F29-1F2F Approved [1]
Onychomycosis EE12.1 Phase 2 [2]
Therapeutic Class
Antifungal Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 291.4
Topological Polar Surface Area (xlogp) 5.6
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 1
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 4.56 mgh/L [3]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 1 mg/L [3]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 2 h [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Clearance
The clearance of drug is 76 L/h [5]
Elimination
Terbinafine is approximately 80% eliminated in urine, while the remainder is eliminated in feces [5]
Half-life
The concentration or amount of drug in body reduced by one-half in 36 hours [3]
Metabolism
The drug is metabolized via the CYP2C9, 2B6, 2C8, 1A2, 3A4, and 2C19 [6]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 92.64339 micromolar/kg/day [7]
Vd
The volume of distribution (Vd) of drug is 947.5 L or 16.6 L/kg [5]
Chemical Identifiers
Formula
C21H25N
IUPAC Name
(E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine
Canonical SMILES
CC(C)(C)C#C/C=C/CN(C)CC1=CC=CC2=CC=CC=C21
InChI
InChI=1S/C21H25N/c1-21(2,3)15-8-5-9-16-22(4)17-19-13-10-12-18-11-6-7-14-20(18)19/h5-7,9-14H,16-17H2,1-4H3/b9-5+
InChIKey
DOMXUEMWDBAQBQ-WEVVVXLNSA-N
Cross-matching ID
PubChem CID
1549008
ChEBI ID
CHEBI:9448
CAS Number
91161-71-6
DrugBank ID
DB00857
TTD ID
D01AYJ
INTEDE ID
DR1557
ACDINA ID
D00663

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Candida Squalene epoxidase (Candi ERG1) TTM9XSU ERG1_CANAL Modulator [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [9]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [9]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [10]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [10]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [9]
Prostaglandin G/H synthase 1 (COX-1) DE073H6 PGH1_HUMAN Substrate [9]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Terbinafine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Ketoconazole DMPZI3Q Moderate Decreased metabolism of Terbinafine caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [50]
Coadministration of a Drug Treating the Disease Different from Terbinafine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Terbinafine and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [51]
Arn-509 DMT81LZ Moderate Increased metabolism of Terbinafine caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [52]
Oliceridine DM6MDCF Major Decreased metabolism of Terbinafine caused by Oliceridine mediated inhibition of CYP450 enzyme. Acute pain [MG31] [53]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Terbinafine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [54]
Desipramine DMT2FDC Moderate Decreased metabolism of Terbinafine caused by Desipramine mediated inhibition of CYP450 enzyme. Attention deficit hyperactivity disorder [6A05] [55]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Terbinafine and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [56]
Alpelisib DMEXMYK Moderate Increased metabolism of Terbinafine caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [57]
Dihydrocodeine DMB0FWL Moderate Decreased metabolism of Terbinafine caused by Dihydrocodeine mediated inhibition of CYP450 enzyme. Chronic pain [MG30] [55]
Sertraline DM0FB1J Moderate Decreased metabolism of Terbinafine caused by Sertraline mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [55]
Vortioxetine DM6F1PU Major Decreased metabolism of Terbinafine caused by Vortioxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [58]
Clomipramine DMINRKW Moderate Decreased metabolism of Terbinafine caused by Clomipramine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [55]
Doxepin DMPI98T Moderate Decreased metabolism of Terbinafine caused by Doxepin mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [55]
Ingrezza DMVPLNC Major Decreased metabolism of Terbinafine caused by Ingrezza mediated inhibition of CYP450 enzyme. Dystonic disorder [8A02] [59]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Terbinafine and Cannabidiol. Epileptic encephalopathy [8A62] [52]
Tolterodine DMSHPW8 Minor Decreased metabolism of Terbinafine caused by Tolterodine mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [60]
Carvedilol DMHTEAO Moderate Decreased metabolism of Terbinafine caused by Carvedilol mediated inhibition of CYP450 enzyme. Heart failure [BD10-BD1Z] [55]
Rifampin DMA8J1G Minor Increased metabolism of Terbinafine caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [61]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Terbinafine and Brentuximab vedotin. Hodgkin lymphoma [2B30] [62]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Terbinafine and Mipomersen. Hyper-lipoproteinaemia [5C80] [63]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Terbinafine and Teriflunomide. Hyper-lipoproteinaemia [5C80] [50]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Terbinafine and BMS-201038. Hyper-lipoproteinaemia [5C80] [64]
Nebivolol DM7F1PA Moderate Decreased metabolism of Terbinafine caused by Nebivolol mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [55]
Pindolol DMD2NV7 Moderate Decreased metabolism of Terbinafine caused by Pindolol mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [55]
Pirfenidone DM6VZFQ Moderate Decreased metabolism of Terbinafine caused by Pirfenidone mediated inhibition of CYP450 enzyme. Idiopathic interstitial pneumonitis [CB03] [52]
PF-06463922 DMKM7EW Moderate Increased metabolism of Terbinafine caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [51]
Primaquine DMWQ16I Moderate Decreased metabolism of Terbinafine caused by Primaquine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [55]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Terbinafine and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [65]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Terbinafine and Idelalisib. Mature B-cell leukaemia [2A82] [66]
Promethazine DM6I5GR Moderate Decreased metabolism of Terbinafine caused by Promethazine mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [55]
Ondansetron DMOTQ1I Moderate Decreased metabolism of Terbinafine caused by Ondansetron mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [55]
Dexfenfluramine DMJ7YDS Moderate Decreased metabolism of Terbinafine caused by Dexfenfluramine mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [55]
Methamphetamine DMPM4SK Moderate Decreased metabolism of Terbinafine caused by Methamphetamine mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [55]
Hydrocodone DMQ2JO5 Moderate Decreased metabolism of Terbinafine caused by Hydrocodone mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [55]
Abametapir DM2RX0I Moderate Decreased metabolism of Terbinafine caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [67]
Lefamulin DME6G97 Moderate Decreased metabolism of Terbinafine caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [68]
Enzalutamide DMGL19D Moderate Increased metabolism of Terbinafine caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [69]
Levomepromazine DMIKFEL Moderate Decreased metabolism of Terbinafine caused by Levomepromazine mediated inhibition of CYP450 enzyme. Psychotic disorder [6A20-6A25] [55]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Terbinafine and Leflunomide. Rheumatoid arthritis [FA20] [50]
Oxamniquine DM2QDX1 Moderate Decreased metabolism of Terbinafine caused by Oxamniquine mediated inhibition of CYP450 enzyme. Schistosomiasis [1F86] [55]
Mesoridazine DM2ZGAN Moderate Decreased metabolism of Terbinafine caused by Mesoridazine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [55]
Aripiprazole DM3NUMH Moderate Decreased metabolism of Terbinafine caused by Aripiprazole mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [70]
Pimozide DMW83TP Major Decreased metabolism of Terbinafine caused by Pimozide mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [50]
Larotrectinib DM26CQR Moderate Decreased metabolism of Terbinafine caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [51]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Terbinafine and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [52]
LEE011 DMMX75K Moderate Decreased metabolism of Terbinafine caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [71]
Pitolisant DM8RFNJ Major Decreased metabolism of Terbinafine caused by Pitolisant mediated inhibition of CYP450 enzyme. Somnolence [MG42] [52]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Terbinafine caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [72]
Methdilazine DMAUHQX Moderate Decreased metabolism of Terbinafine caused by Methdilazine mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [55]
Trimeprazine DMEMV9D Moderate Decreased metabolism of Terbinafine caused by Trimeprazine mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [55]
Propafenone DMPIBJK Moderate Decreased metabolism of Terbinafine caused by Propafenone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [55]
Flecainide DMSQDLE Moderate Decreased metabolism of Terbinafine caused by Flecainide mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [55]
Amiodarone DMUTEX3 Moderate Decreased metabolism of Terbinafine caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [50]
⏷ Show the Full List of 52 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Carmellose sodium E00625 Not Available Disintegrant
Crospovidone E00626 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Hypromellose E00634 Not Available Coating agent
Magnesium stearate E00208 11177 lubricant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Hydrophobic colloidal silica E00285 24261 Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
⏷ Show the Full List of 8 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Terbinafine Hydrochloride eq 250mg base tablet eq 250mg base Tablet Oral
Terbinafine 250 mg tablet 250 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality. Ther Clin Risk Manag. 2005 Dec;1(4):299-306.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 FDA Approved Drug Products: Lamisil Terbinafine Hydrochloride Oral Tablets
4 BDDCS applied to over 900 drugs
5 Darkes MJ, Scott LJ, Goa KL: Terbinafine: a review of its use in onychomycosis in adults. Am J Clin Dermatol. 2003;4(1):39-65.
6 Baladi MG, Forster MJ, Gatch MB, Mailman RB, Hyman DL, Carter LP, Janowsky A: Characterization of the Neurochemical and Behavioral Effects of Solriamfetol (JZP-110), a Selective Dopamine and Norepinephrine Reuptake Inhibitor. J Pharmacol Exp Ther. 2018 Aug;366(2):367-376. doi: 10.1124/jpet.118.248120. Epub 2018 Jun 11.
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
9 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
10 Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. Drug Metab Dispos. 1999 Sep;27(9):1029-38.
11 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
12 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
13 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
14 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
15 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
16 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
17 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
18 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
19 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
20 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
21 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
22 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
23 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
24 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
25 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
26 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
27 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
28 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
29 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
30 Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
31 Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
32 Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
33 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
34 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
35 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
36 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
37 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
38 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
39 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
40 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
41 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
42 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
43 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
44 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
45 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
46 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
47 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
48 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
49 Peroxidative free radical formation and O-demethylation of etoposide(VP-16) and teniposide(VM-26). Biochem Biophys Res Commun. 1986 Feb 26;135(1):215-20.
50 Canadian Pharmacists Association.
51 Cerner Multum, Inc. "Australian Product Information.".
52 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
53 Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
54 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
55 AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
56 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
57 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
58 Product Information. Brintellix (vortioxetine). Takeda Pharmaceuticals America, Lincolnshire, IL.
59 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
60 Brynne N, Svanstrom C, AbergWistedt A, Hallen B, Bertilsson L "Fluoxetine inhibits the metabolism of tolterodin-pharmacokinetic implications and proposed clinical relevance." Br J Clin Pharmacol 48 (1999): 553-63. [PMID: 10583026]
61 Product Information. Lamisil (terbinafine). Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
62 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
63 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
64 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
65 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
66 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
67 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
68 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
69 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
70 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
71 DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
72 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.